ERBB2 and neoplasm: Of 4391 patients, 2711 (62%) were postmenopausal women and 20 (<1%) were men, 2337 (53%) were node positive, 2520 (57%) had grade 3 disease, 3196 (73%) had oestrogen-receptor-positive and/or progesterone-receptor-positive tumours, and 831 (19%) had HER2-positive tumours based on local assessments.